News | Point of Care Testing | December 22, 2015

Trinity Biotech Submits High Sensitivity Troponin I Product to FDA

Assay and analyzer work together to diagnose myocardial infarction in the emergency department within 15 minutes

December 22, 2015 — Trinity Biotech plc announced submission of its Meritas Point of Care Analyzer and Meritas cardiac troponin-I (cTnI) point-of-care assay for U.S. Food and Drug Administration (FDA) 510(k) clearance. The company is seeking clearance for both systems for use in the diagnosis of myocardial infarction (MI).

The cTnI assay will enable healthcare professionals to quickly determine patient cardiac status in emergency department settings, to accelerate patient care and to reduce overall costs of delivering health care.

The Meritas cTnI assay is run on the Meritas Point of Care Analyzer. The single-use, pre-calibrated cTnI assay is simple to use, and delivers cTnI results in about 15 minutes in both whole blood and plasma samples. The assay combines sensitive antibody reagents and the use of advanced injection molding technologies to create high-fidelity micropillar structures to control sample fluidics. Clinical data was collected at 14 geographically dispersed locations across the United States, and MIs were determined by a panel of independent adjudicators. 

Clinical performance results of the product at the time of admission to the hospital emergency room demonstrated 66 percent sensitivity and 84 percent specificity for whole blood; results were 78 percent and 95 percent, respectively, for plasma.

For more information: www.trinitybiotech.com


Related Content

News | Point of Care Testing

August 5, 2019 — A West Virginia-based rural medical outreach event showcased the use of point-of-care technology in an ...

Home August 05, 2019
Home
News | Point of Care Testing

July 26, 2017 — Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of ...

Home July 26, 2017
Home
News | Point of Care Testing | Dave Fornell

July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is once ...

Home July 17, 2017
Home
Feature | Point of Care Testing | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios

Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on ...

Home May 05, 2017
Home
Technology | Point of Care Testing

January 27, 2017 — HyperMed Imaging Inc. announced that it has received clearance from the U.S. Food and Drug ...

Home January 27, 2017
Home
Feature | Point of Care Testing | Ravi Chawat

Point of care testing devices are gaining widespread approval for prompt medical diagnoses, especially in cardiology and ...

Home December 30, 2016
Home
Feature | Point of Care Testing

December 7, 2016 — Abbott has filed a complaint to terminate its proposed acquisition of Alere based on the substantial ...

Home December 07, 2016
Home
Technology | Point of Care Testing

November 10, 2016 — Siemens Healthineers announced U.S. Food and Drug Administration (FDA) 510(k) clearance for a hand ...

Home November 10, 2016
Home
News | Point of Care Testing

February 3, 2016 — Abbott and Alere Inc. announced a definitive agreement for Abbott to acquire Alere. Under the terms ...

Home February 03, 2016
Home
News | Point of Care Testing

October 13, 2015 — The Lancet published results online that show Abbott’s ARCHITECT STAT High Sensitive Troponin-I ...

Home October 13, 2015
Home
Subscribe Now